Chiquita Brooks-LaSure (Photo by Caroline Brehman/CQ Roll Call via AP Images)

New Biden pro­pos­al would ex­pose the ac­tu­al cost of drugs cov­ered by Med­ic­aid

Build­ing off its new ne­go­ti­at­ing pow­ers thanks to the In­fla­tion Re­duc­tion Act, the Biden ad­min­is­tra­tion and Cen­ters for Medicare and Med­ic­aid Ser­vices (CMS) late yes­ter­day pro­posed a new rule that could help states bet­ter un­der­stand what the most ex­pen­sive drugs on the mar­ket to­day ac­tu­al­ly cost to man­u­fac­ture and dis­trib­ute.

The pro­pos­al would give CMS and states new tools, like a drug price ver­i­fi­ca­tion sur­vey, which could help ver­i­fy drug prices and in­crease trans­paren­cy about why cer­tain drug prices are ex­pen­sive for Med­ic­aid, and help states bet­ter ne­go­ti­ate what they pay for high-cost drugs.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters